PubRank

M C Alessi

Author PubWeight™ 78.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Granulocyte-endothelium initial adhesion. Analysis of transient binding events mediated by E-selectin in a laminar shear flow. Biophys J 1993 2.86
2 C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007 2.19
3 The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia 2009 1.82
4 Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996 1.80
5 Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988 1.77
6 Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988 1.68
7 Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007 1.67
8 Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000 1.64
9 Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004 1.52
10 Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987 1.44
11 Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991 1.41
12 Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost 1989 1.38
13 Cutaneous necrosis associated with acquired severe protein S deficiency. Thromb Haemost 1993 1.37
14 Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986 1.30
15 Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001 1.24
16 Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997 1.21
17 Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000 1.16
18 PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997 1.16
19 Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 1995 1.12
20 Iloprost and salvage of a free flap. Br J Plast Surg 1996 1.09
21 Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002 1.08
22 Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996 1.02
23 Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells. Infect Immun 1990 1.02
24 Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007 1.02
25 The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost 2003 1.00
26 Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992 1.00
27 Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab 1987 0.96
28 Adipose tissue expression of gelatinases in mouse models of obesity. Thromb Haemost 2001 0.96
29 Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989 0.96
30 Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol 1998 0.94
31 Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001 0.93
32 Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol 2005 0.93
33 Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 1989 0.93
34 PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 1999 0.92
35 Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993 0.92
36 Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol. Thromb Haemost 1985 0.91
37 Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997 0.91
38 Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996 0.91
39 Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost 1999 0.90
40 Protein S deficiency and HIV infection. N Engl J Med 1991 0.89
41 Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987 0.89
42 Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men. Am J Physiol Endocrinol Metab 2007 0.88
43 Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level. Arterioscler Thromb Vasc Biol 1997 0.88
44 Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest 1993 0.86
45 Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998 0.85
46 Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis 2004 0.84
47 Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. Blood 1996 0.84
48 Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 1992 0.83
49 Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994 0.83
50 Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999 0.83
51 Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003 0.82
52 Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001 0.81
53 In vivo assessment of murine elastase-induced abdominal aortic aneurysm with high resolution magnetic resonance imaging. Eur J Vasc Endovasc Surg 2012 0.81
54 Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost 1986 0.81
55 The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 2000 0.81
56 Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2001 0.80
57 Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2009 0.80
58 Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost 2008 0.80
59 [Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases]. Rev Med Interne 2001 0.80
60 Pathophysiology of fibrinolysis. Baillieres Clin Haematol 1995 0.79
61 Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost 2005 0.79
62 Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemost 1987 0.79
63 Resistance to activated protein C--diagnostic strategy in a laboratory of haemostasis. Thromb Haemost 1995 0.79
64 Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000 0.79
65 New direct assay of free protein S antigen applied to diagnosis of protein S deficiency. Thromb Haemost 1996 0.78
66 Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model. J Thromb Haemost 2014 0.78
67 Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000 0.78
68 Characterization of epitheloid cells from human omentum: comparison with endothelial cells from umbilical veins. Thromb Haemost 1991 0.78
69 Purpura fulminans in a patient homozygous for a mutation in the protein C gene--prenatal diagnosis in a subsequent pregnancy. Thromb Haemost 1996 0.78
70 Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991 0.78
71 Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung. J Thromb Haemost 2007 0.78
72 Systemic inhibition and liver-specific over-expression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice. J Thromb Haemost 2014 0.77
73 Plasma plasminogen activator inhibitor activity in rats with nutritionally induced insulin resistance. Thromb Haemost 1995 0.77
74 CD11b+ leukocyte microparticles are associated with high-risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. J Thromb Haemost 2011 0.76
75 A three-generation family presenting five cases of homozygosity for the 20210 G to A prothrombin variant. Thromb Haemost 1998 0.76
76 Relations between hemostatic variables, insulin resistance and inflammation. Hematol J 2004 0.75
77 Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. J Thromb Haemost 2008 0.75
78 Statins: maid-of-all-work in cardiovascular diseases! Arch Mal Coeur Vaiss 2003 0.75
79 [Aging of the arterial wall: endothelium, thrombosis and fibrinolysis]. Ann Cardiol Angeiol (Paris) 1991 0.75
80 Acquired protein S deficiency, likely due to anti-PS autoantibodies, following a thrombotic event in a patient with a systemic lupus erythematosus. Thromb Haemost 1997 0.75
81 Lupus anticoagulant in silica-induced scleroderma. Clin Rheumatol 1992 0.75
82 [Intradural hematoma of the foramen magnum associated with factor XIII deficiency]. Rev Neurol (Paris) 1994 0.75
83 Relation between plasma PAI activity and adipsin levels. Thromb Haemost 1995 0.75
84 Venous occlusion does not induce the release of thrombomodulin from endothelial cells in patients with thromboembolic disease. Thromb Haemost 1992 0.75
85 [Mixed cryoglobulinemia in hepatitis C virus infection. 10 cases]. Presse Med 1991 0.75
86 Lupus anticoagulants and antiphospholipid antibodies: comparison of clotting tests with an immunological assay. Thromb Res 1990 0.75
87 [Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty]. Arch Mal Coeur Vaiss 2006 0.75
88 Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemost 1987 0.75
89 Up-regulated expression of plasminogen activator inhibitor-1 in Hep G2 cells: interrelationship between insulin and insulin-like growth factor 1. Thromb Haemost 1995 0.75
90 TAFI levels in patients with acute myocardial infarction treated with thrombolysis. J Thromb Haemost 2005 0.75
91 Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost 1999 0.75
92 Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model. J Thromb Haemost 2014 0.75
93 [Ophthalmic vein thrombosis and G1691A mutation of factor V gene]. Presse Med 1999 0.75
94 Modulation of tPA, PAI-1 and PAI-2 antigen and mRNA levels by EGF in the A431 cell line. Blood Coagul Fibrinolysis 1990 0.75
95 Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res 1993 0.75
96 Fibrinogen, obesity and insulin resistance. Blood Coagul Fibrinolysis 1999 0.75
97 Intraperitoneal insulin administration does not modify plasminogen activator inhibitor 1 levels in IDDM patients. Diabetes Care 1994 0.75
98 [Thromboembolic disease and anomalies of fibrinolysis]. Ann Med Interne (Paris) 1986 0.75
99 [Anti-activator inhibitors of plasminogen]. Ann Biol Clin (Paris) 1987 0.75
100 [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein]. J Mal Vasc 1987 0.75
101 [Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. Arch Mal Coeur Vaiss 2006 0.75
102 Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. Diabete Metab 1992 0.75
103 [Acrosyndrome disclosing protein S deficiency in human immunodeficiency virus infection]. Ann Med Interne (Paris) 1992 0.75
104 Rapid detection of factor XIII Val34Leu by allele specific PCR. Thromb Haemost 1999 0.75
105 Protein S deficiency: different biological phenotypes according to the assays used. Thromb Haemost 1998 0.75
106 [Acute stent thrombosis due to resistance to clopidogrel ? A case report]. Arch Mal Coeur Vaiss 2007 0.75
107 Arg578Gln mutations in the von Willebrand factor gene in three unrelated cases of type IIB von Willebrand disease. Blood Coagul Fibrinolysis 1993 0.75
108 Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator. Semin Thromb Hemost 1989 0.75
109 [Thromboembolic risk remains uncertain in protein C deficiency]. Presse Med 1985 0.75
110 Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. J Thromb Haemost 2010 0.75